<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013648</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 21-13</org_study_id>
    <nct_id>NCT02013648</nct_id>
  </id_info>
  <brief_title>Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)</brief_title>
  <official_title>Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase III open-label, multicenter trial evaluating standard induction
      therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose
      cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase III open-label, multicenter trial evaluating standard induction
      therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose
      cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML;
      in the investigational arm, consolidation therapy is followed by a one-year maintenance
      therapy with dasatinib. Patients with molecular disease persistence or molecular relapse as
      assessed by quantitative RQ-PCR for the CBF fusion transcripts will be eligible for
      hematopoietic stem cell transplantation before overt hematologic relapse occurs. Primary
      endpoint is event-free survival.

      AML patients will be assessed for the CBF fusion genes in one of two AMLSG central
      laboratories within 48 hours of diagnosis, and only patients with CBF-AML will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>4 years</time_frame>
    <description>To assess event-free survival (EFS) after intensive induction (daunorubicin and cytarabine) and consolidation (high-dose cytarabine) chemotherapy with or without dasatinib in patients with CBF-AML</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death (CID)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIA analysis</measure>
    <time_frame>4 years</time_frame>
    <description>Pharmacodynamic inhibition of KIT as assessed by the KIT plasma inhibitory assay (PIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>7 months (standard arm) / 19 months (investigational arm)</time_frame>
    <description>Type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03), timing and relatedness of non-hematologic toxicity observed during different treatment cycles.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">277</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy:
Patients will receive induction therapy (one or two cycles) with daunorubicin 60 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7. No dose reduction is planned in elderly (&gt;60 years) patients.
Optional second induction cycle:
Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.
Consolidation therapy:
Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (&gt;60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.
Follow-up period:
There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy:
Patients will receive induction therapy (one or two cycles) with daunorubicin 60 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7. Patients will receive dasatinib 100 mg once daily (QD) on days 8-21.
Opt. 2nd induction cycle:
Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.
Consolidation therapy:
Patients will receive 4 consolidation cycles. Treatment consists of high-dose cytarabine 3 g/m2 (&gt;60 years: 1 g/m2) q12h, days 1-3 administered IV over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21.
Maintenance therapy:
Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <arm_group_label>Investigational arm</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Investigational arm</arm_group_label>
    <other_name>ARA-cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Investigational arm</arm_group_label>
    <other_name>Daunoblastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Core-binding factor (CBF) AML with molecular diagnosis of RUNX1-RUNX1T1 fusion
             transcript resulting from t(8;21)(q22;q22) (or a variant form) or of CBFB-MYH11 fusion
             transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in one of
             the central AMLSG reference laboratories (Ulm, Hannover)

          -  Age ≥ 18; there is no upper age limit

          -  No prior chemotherapy for leukemia except hydroxyurea for up to 5 days during the
             diagnostic screening phase

          -  Non-pregnant and non-nursing. Due to the unknown teratogenic potential of dasatinib in
             humans, pregnant or nursing patients may not be enrolled. Women of childbearing
             potential (WOCBP) must have a negative serum or urine pregnancy test within a
             sensitivity of at least 25 mIU/mL with-in 72 hours prior to registration. Women of
             child-bearing potential must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable methods of birth control - one highly effective
             method (e.g., IUD, hormonal, tubal ligation, or partner's vasectomy), and one
             additional effective method (e.g., latex condom, diaphragm, or cervical cap) - AT THE
             SAME TIME, at least four weeks before she begins dasatinib therapy. &quot;Women of
             childbearing potential&quot; is defined as a sexually active mature woman who has not
             undergone a hysterectomy or who has had menses at any time in the preceding 24
             consecutive months.

          -  Men must agree not to father a child and must use a latex condom during any sexual
             contact with women of childbearing potential while taking dasatinib and for 3 months
             after therapy is stopped, even if they have undergone a successful vasectomy.

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Performance status WHO &gt;2

          -  Pulmonary edema and/or pleural/pericardial effusion within 14 days of day 1. If
             edema/effusion resolves to CTC Grade ≤1, patients can be treated with dasatinib.

          -  Patients with ejection fraction &lt;50% by echocardiography within 14 days of day 1

          -  Organ insufficiency (creatinine &gt;1.5x upper normal serum level; bilirubin, AST or AP
             &gt;2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or
             restrictive ventilation disorder)

          -  Uncontrolled infection

          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin
             cancers. Patients are not considered to have a &quot;currently active&quot; malignancy, if they
             have completed therapy and are considered by their physician to be at less than 30%
             risk of relapse within one year.

          -  Severe neurological or psychiatric disorder interfering with ability of giving an
             informed consent

          -  Known positive for HIV, active HBV, HCV, or Hepatitis A infection

          -  Bleeding disorder independent of leukemia

          -  No consent for registration, storage and processing of the individual disease
             characteristics and course as well as information of the family physician and/or other
             physicians involved in the treatment of the patient about study participation.

          -  No consent for biobanking.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Doehner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hartmut Doehner, Prof. Dr.</last_name>
    <phone>0049-731-500-</phone>
    <phone_ext>45501</phone_ext>
    <email>hartmut.doehner@uniklinik-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Paschka, Dr.</last_name>
    <phone>0049-731-500</phone>
    <phone_ext>45746</phone_ext>
    <email>peter.paschka@uniklinik-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin V</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Nachbaur, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>David Nachbaur, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Aschauer, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Gregor Aschauer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid Machherndl-Spandl, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sigrid Machherndl-Spandl, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der PMU</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Richard Greil, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanuschkrankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Koller, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth Koller, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MVZ Osthessen</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Distelrath, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Heinz-Gert Höffkes, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrea Distelrath, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-August Horst, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Sebastian Buske</last_name>
    </contact_backup>
    <investigator>
      <last_name>Heinz-August Horst, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow, Klinik für Hämatologie</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Bitz, Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Peter Reichardt, PD Dr. med.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Bitz, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Scholz, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Annette Dieing, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Christian Scholz, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Lore Marretta, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Maike de Wit, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Westermann, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Anne Flörcken, Dr. med.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jörg Westermann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Mayer, Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Dominik Wolf, Prof.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karin Mayer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Krauter, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Miriam Ahlborn, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Krauter, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hertenstein, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Kaun, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Bernd Hertenstein, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt Medizinische Klinik V</name>
      <address>
        <city>Darmstadt</city>
        <zip>64276</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helaga Bernhard, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Arne Brecht, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Helga Bernhard, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40001</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Germing, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Mustafa Kondakci, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Germing, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Schwänen, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Swen Wessendorf, PD Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Carsten Schwänen, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Helge Menzel, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nadezda Basara, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lübbert, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Ralph Wäsch, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Lübbert, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelm-Anton-Hospital gGmbH</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Runde, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Veronika Hoffmann-Schneider, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Volker Runde, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Wulf, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Tobias Pukrop, PD Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gerald Wulf, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Fiedler, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Maxim Kebenko, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Walter Fiedler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Hanau GmbH</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Sendler, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Burk, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrea Sendler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Kirchner, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Gita Maher, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hartmut Kirchner, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Heuser, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Felicitas Thol, PD Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Heuser, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Markus Lindauer, Dr. med.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Uwe Martens, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital Klinikum der Ruhr-Universität</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Schultheis, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Dirk Strumberg, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Beate Schultheis, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Bentz, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mark Ringhoffer, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämato-Onkologie im Caritas Krankenhaus</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kremers, Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Gero Leonhard-Helmschmidt, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stephan Kremers, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe GmbH</name>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Hesse</last_name>
    </contact>
    <contact_backup>
      <last_name>Frank Hartmann, Prof Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tanja Hesse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Märkische Kliniken GmbH</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Heil, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Serap Gülüc, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gerhard Heil, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ-Klinikum der Otto-von Guericke-Universität</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Heinicke, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Lynn Hanus, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thomas Heinicke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik und Poliklinik Universitätsmedizin der Johannes Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Radsak, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Kindler, PD Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Markus Radsak, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Joachim Tischler, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Griesshammer, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hans-Joachim Tischler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Armin Snaga, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Götze, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Mareike Verbeek, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Katharina Götze, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Jakob, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Irmgard Dresel, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andreas Jakob, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PIUS Hospital</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Griesinger, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Imme Conradi, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Frank Griesinger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Krämer, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jochen Casper, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Doris Krämer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Südhoff, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Thorsten Nitsch, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thomas Südhoff, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caritasklinkum Saarbrücken St. Theresia</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Matzdorff, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Karen Benesch</last_name>
    </contact_backup>
    <investigator>
      <last_name>Axel Matzdorff, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Schleicher, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Dennis Hahn, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jan Schleicher, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vinzenz von Paul Kliniken gGmbH Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Denzlinger, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Guido Hausner, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Claudio Denzlinger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Mahlenberg, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Boris Meuter, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rolf Mahlberg, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Salih, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Marcus Schittenhelm, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Helmut Salih, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Zentrum für Innere Medizin</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Döhner, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Peter Paschka, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hartmut Döhner, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Brugger, Prof.</last_name>
    </contact>
    <contact_backup>
      <last_name>Friedemann Köhler, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Wolfram Brugger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd</name>
      <address>
        <city>Werden</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Wattad</last_name>
    </contact>
    <contact_backup>
      <last_name>Peter Reimer, Prof. Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mohammed Wattad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Schostok, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Konstantin Koutcher, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Silke Schostok, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Hartmut Doehner</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>Core Binding Factor (CBF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

